Asia Fresh News

Asia Fresh Stories

Archive for April 18th, 2014

Thomson Reuters Names 2014 Drugs to Watch

leave a comment »

Analysis points to three potential blockbusters: Sovaldi, Anoro Ellipta and Idelalisib entering market this year

PHILADELPHIA, April 16, 2014 /PRNewswire/ — The Intellectual Property & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, released its annual forecast of the leading drugs to watch in 2014, including three potential blockbuster treatments anticipated to attain more than $1 billion in sales through 2019, after entering the marketplace this year.

The study utilized Cortellis™ Competitive Intelligence, the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content, to create a Market Insight report identifying drugs that will have a significant impact on the marketplace in 2014 and for years to come.

The analysis points to three potential blockbuster drugs:

Sovaldi: Gilead’s oral NS5B ploymersase inhibitor for treating hepatitis C virus (HCV) was approved by the FDA in December 2013 and is expected to reach a consensus of $2.4 billion in sales in 2014, rising to its peak in sales in an estimated $9.1 billion in 2017.
Anoro Ellipta: GlaxoSmithKline/Theravance’s Anoro Ellipta, which contains two bronchodilators for the long-term, once-daily maintenance treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), which is predicted to outsell its developers’ 2013 potential blockbuster Relovair in the COPD field, with forecasted sales of $3 billion through 2019.
Idelalisib: Gilead filed this oral P13K p110-delta subunit inhibitor for US approval for indolent non-Hodgkin’s lymphoma in September 2013 and for European approval for chronic lymphocytic leukemia (CLL) and INHL in October 2013. A US filing for CLL is also planned. This treatment demonstrated significant efficacy in a phase III CLL trial; however, idelalisib faces stiff competition in the CLL marketplace.

“These treatments are expected to be the highest performing from our list of drugs to watch in 2014,” said Charlotte Jago, a senior editor for the Thomson Reuters Life Science business, and author of the Market Insight report. “That is not to say, however, that these are the only drugs of high potential this year. To the contrary, there are several other therapies we’ve identified and which are also worth keeping an eye on.”

Among those worthy of additional attention are Eli Lilly’s long-acting GLP-1 analog dulaglutide for diabetes and its anti-VEGFR2 mAb Cyramza for gastric cancer, as well as MannKind’s inhaled insulin product Afrezza. This will be the third filing for Afrezza since 2009, after the FDA twice requested further information.

“It is interesting to watch the transformation from yesterday’s blockbuster drug era to that of the current environment, where precision medicine and drug repositioning are on center stage,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “That said, we see three strong potentials of blockbuster caliber this year. As the pharmaceutical industry searches for replacement revenue streams, our Drugs to Watch report is a valuable tool for identifying therapies that have blockbuster potential, as well as other drugs with strong revenue indicators..”

The Thomson Reuters Market Insight report also includes an update on the 2013 Drugs to Watch, including Vascepa (Amarin), Pomalyst (Celgene), Kadcyla (Roche), and Relovair (GlaxoSmithKline, Thervance).

View the Market Insight report or visit the Thomson Reuters Life Science Connect blog for a synopsis of the report and for other posts providing a view into the Life Sciences industry’s latest news and trends.

Learn more about Cortellis for Competitive Intelligence.

Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. For more information, go to http://www.thomsonreuters.com.

CONTACT

Jen Breen
+1 215 823 1791
jennifer.breen@thomsonreuters.com

Molly Malone
+1 215 292-8939
Molly.malone@thomsonreuters.com
Source: Thomson Reuters

Written by asiafreshnews

April 18, 2014 at 12:09 pm

Posted in Uncategorized

AmCham Singapore Selects the Yellow Ribbon Fund as Its 2014 Adopted Charity

leave a comment »

SINGAPORE, April 16, 2014 /PRNewswire/ — The American Chamber of Commerce in Singapore (AmCham) is pleased to announce that it has selected the Yellow Ribbon Fund as its Adopted Charity for 2014. This selection extends the relationship with the Yellow Ribbon Fund as AmCham also chose the charity as its inaugural Adopted Charity last year.

Launched by the former Singaporean President S. R. Nathan in 2004, the Yellow Ribbon Fund aims to administer funding to the development and implementation of reintegration programs for inmates and ex-offenders.

Simon Kahn, Chairman of the AmCham Board of Governors, explained, “Over our more than 40 years in Singapore, AmCham and its members have a long history of giving back to the community. We chose the Yellow Ribbon Fund as our first Adopted Charity last year because of its unique ability to positively influence the business environment in Singapore through training potential members of the workforce. Yellow Ribbon does an outstanding job helping ex-offenders reintegrate into and reinvigorate society. We couldn’t be prouder to continue our relationship and we look forward to working together throughout the year.”

Chairman of the Yellow Ribbon Fund, Phillip Tan added, “As the first national charitable fund dedicated to help garner support for offender-related work, the Yellow Ribbon Fund is committed to help ex-offenders and their families reintegrate into the community. AmCham’s strong support helps to support the work that we do and the Yellow Ribbon campaign needs everyone in Singapore to pitch in; as the largest foreign business chamber in Singapore, AmCham is demonstrating its support for our community’s future.”

Vice Chair of the AmCham Board of Governors Colin Low continued, “Although I am Singaporean, I only recently visited Changi Prison and was introduced to the Yellow Ribbon Fund Committee and its programs for the first time. There, I witnessed first-hand the work that Yellow Ribbon does in helping men and women receive a second chance to be productive members of society. More inspiring, Yellow Ribbon Fund programs encourage the inmates to form bonds and support for their family in a wide variety of ways. Yellow Ribbon’s efforts are remarkable, inspiring, and humbling. All of us at AmCham are simply proud to be associated with the organization for an even better Singapore!”

AmCham and its member companies engage in corporate social responsibility activities throughout the year. The flagship event is AmCham’s annual Corporate Community Day. Last year’s event brought together over 2,000 volunteers from 82 organizations on a single day to benefit 9,000 individuals across Singapore. Working with Yellow Ribbon, AmCham’s own event hosted 20 ex-offenders and their families at the Science Centre Singapore, where they participated in a treasure hunt, carried out science experiments, and enjoyed a day of family fun together. AmCham looks forward to working with Yellow Ribbon again this year in designing an event to support ex-offenders’ success with their second chances.

Background
AmCham selects an Adopted Charity and organizes Corporate Community Day to encourage member companies and their employees to commit to volunteerism throughout the year.

The American Chamber of Commerce in Singapore is the leading international business association in Singapore, with over 5,000 members representing more than 750 companies. American companies’ direct investment in Singapore exceeds an estimated S$170 billion.

For further information, contact:
Thomas H. McNutt
Head of Government & Public Affairs
Phone: +65-6597-5732
Email: tmcnutt@amcham.org.sg
Source: The American Chamber of Commerce in Singapore

Written by asiafreshnews

April 18, 2014 at 11:40 am

Posted in Uncategorized